Canada markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3800-0.0300 (-0.68%)
At close: 04:00PM EDT
4.4191 +0.04 (+0.89%)
After hours: 07:59PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 911.18M
Enterprise Value 1.35B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)2.56
Price/Book (mrq)56.59
Enterprise Value/Revenue 4.07
Enterprise Value/EBITDA -11.58

Trading Information

Stock Price History

Beta (5Y Monthly) 1.93
52-Week Change 3-41.12%
S&P500 52-Week Change 323.06%
52 Week High 39.0700
52 Week Low 34.2700
50-Day Moving Average 35.1934
200-Day Moving Average 36.0736

Share Statistics

Avg Vol (3 month) 33.11M
Avg Vol (10 day) 33.15M
Shares Outstanding 5206.15M
Implied Shares Outstanding 6206.15M
Float 8190.88M
% Held by Insiders 11.22%
% Held by Institutions 188.14%
Shares Short (Mar 28, 2024) 432.25M
Short Ratio (Mar 28, 2024) 49.45
Short % of Float (Mar 28, 2024) 417.40%
Short % of Shares Outstanding (Mar 28, 2024) 415.65%
Shares Short (prior month Feb 29, 2024) 429.1M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -68.36%
Operating Margin (ttm)-40.41%

Management Effectiveness

Return on Assets (ttm)-11.57%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)331.41M
Revenue Per Share (ttm)1.72
Quarterly Revenue Growth (yoy)17.40%
Gross Profit (ttm)N/A
EBITDA -95.91M
Net Income Avi to Common (ttm)-226.54M
Diluted EPS (ttm)-1.1800
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)388.99M
Total Cash Per Share (mrq)1.89
Total Debt (mrq)848.71M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.31
Book Value Per Share (mrq)-2.21

Cash Flow Statement

Operating Cash Flow (ttm)-95.14M
Levered Free Cash Flow (ttm)-67.23M